「生物制药公司」 瑞博生物-B 暗盘大涨29%，不计手续费，一手账面赚3426港元。
瑞博生物创立于2007年，是一家从事小核酸药物研究和开发，尤其专注于siRNA疗法的生物制药公司。拥有一款用于治疗血栓性疾病的核心产品RBD4059（靶向FXI的siRNA），研发管线中共有7款自研药物资产处于临床试验阶段，涉及心血管、代谢类、肾脏和肝脏疾病的7种适应症，其中4款处于2期临床试验中。
2025年上半年瑞博生物收入1亿元（人民币，下同），按年升56.6%，研发开支1.3亿元，减少4.2%，期内亏损9776.5万元，收窄30.9%。
瑞博生物引入Arc Avenue、Bright Stone、华夏基金、大成国际及大成基金、Erik Selin Fastigheter AB、Himension Fund、IvyRock、Mingxin Growth Ventures、Springs Capital （Hong Kong）、泰康人寿、拾贝能信、自然拾贝及Huatai Capital Investment Limited（关于华泰场外掉期），共认购1亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
